Media

Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Orexo has repurchased 14 percent of own corporate bonds

The Lancet Haematology Publishes Results from Oncopeptides’ Multicenter, International Phase 1/2 Study (O-12-M1)

First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models

Fusion Pharmaceuticals Appoints James J. O’Leary, M.D. As Chief Medical Officer

Dr. Matthias Friebe joins Camel-IDS as acting Chief Technology Officer

Accelerated road to market approval for CERAMENT® G in the US – BONESUPPORT[TM] submits De Novo application

Nordic Nanovector Appoints Dr Dominic Smethurst as Interim Chief Medical Officer

Oncopeptides provides update regarding COVID-19 impact on the melflufen clinical program